Connect with us
PBEs have doubled the number of clinical trials in the last five years, and their success rates are higher than those of their 'big sisters', according...
Moderna's commitment to Spain was made clear last Tuesday, June 7th, when representatives of the US biotech company met with the President of the Government, Pedro...
VB Devices closed 2021 with sales of $339,000 (€315,000), the target for 2022 is to achieve $977,000 (€909,000) and for 2023 to exceed $1.6 million (€1.5...
Minoryx Therapeutics, based in Mataró (Barcelona), will also finance the activities necessary to be able to proceed with the approval of leriglitazone in the United States...
Immuno-oncology and molecular oncology are two of Sanofi's most promising bets to tackle some of the most difficult-to-treat cancers. While immuno-oncology research is focused on finding...
Rovi's increase was mainly driven by the strength of the third-party manufacturing business, which grew by 167%. Farma posted a net profit of $28 million (€26.6...
There are currently five million people with spinal cord injuries worldwide and this figure is increasing with half a million more people every year, according to...
Pfizer closed the first quarter of 2022 with a profit of $7.86 billion, up from $4.88 billion collected between January and March 2021. The pharma developer...
According to regulations, an accelerated authorization requires a confirmatory trial, so Pharma Mar announced in December 2021 the start of a confirmatory Phase III clinical trial,...
Microviable Therapeutics emerged as a spin-off from Ipla-Csic in 2016, focused on the development of technologies and therapeutic products derived from the microbiota. Microviable Therapeutics will...